title: The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists.
abstract: OBJECTIVE
  Recent randomized controlled data suggest that neoadjuvant chemotherapy (NACT) with interval debulking (ID) may produce similar overall survival and progression free survival compared to standard primary cytoreduction followed by chemotherapy. The object of our study was to assess current patterns of care among members of the Society of Gynecologic Oncologists (SGO), specifically collating their opinions on and use of NACT for advanced stage ovarian cancer.
  
  
  METHODS
  A 20-item questionnaire was sent to all working e-mail addresses of SGO members (n=1137). The data was collected and analyzed using descriptive statistics with commercially available online survey software. The Chi-square test for independence was used to determine differences in responses between groups.
  
  
  RESULTS
  Of 339 (30%) responding members, most rarely employ NACT, with 60% of respondents using NACT in less than 10% of advanced stage ovarian cancer cases. Respondents did not consider available evidence sufficient to justify NACT followed by ID (82%), nor did most think it should be preferred (74%). Sixty-two percent of respondents thought it was impossible to accurately predict preoperatively whether an optimal cytoreduction is possible. Thirty-nine percent believed that women with bulky upper abdominal disease on preoperative imaging would benefit from NACT versus primary debulking. If gross disease were found at ID, 43% would continue to treat with IV chemotherapy, and 42% would place an IP port if optimally cytoreduced. When ID reveals microscopic disease, 51% would continue IV treatment and the remaining IP therapy. Eighty-six percent of the respondents believed that both biological and surgical factors determine patient outcomes.
  
  
  CONCLUSIONS
  The majority of responding SGO members do not treat patients with NACT followed by ID. Currently available studies of NACT/ID have been insufficient to convince most gynecologic oncologists to incorporate it into practice. Our results provide a benchmark against which further research can assess the penetration of NACT/ID into clinical practice.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine and Siteman Cancer Center, 4911 Barnes Jewish Hospital Plaza, Box 8064, St Louis, MO 63110, USA. dewdneys@wustl.edu
authors.forename: Summer B
authors.initials: SB
authors.lastname: Dewdney
authors.forename: B J
authors.initials: BJ
authors.lastname: Rimel
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Reinhart
authors.forename: Nora T
authors.initials: NT
authors.lastname: Kizer
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Brooks
authors.forename: L Stewart
authors.initials: LS
authors.lastname: Massad
authors.forename: Israel
authors.initials: I
authors.lastname: Zighelboim
mesh_terms: D017024:Chemotherapy, Adjuvant; D005260:Female; D006176:Gynecology / Q000379:methods*; D006801:Humans; D008495:Medical Oncology / Q000379:methods*; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010818:Practice Patterns, Physicians'; D011795:Surveys and Questionnaires